{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T03:56:24Z","timestamp":1794628584957,"version":"4.9.1"},"reference-count":36,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100013995","name":"Sanofi Genzyme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013995","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["trasci.com","clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transfusion and Apheresis Science"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.transci.2024.103934","type":"journal-article","created":{"date-parts":[[2024,4,18]],"date-time":"2024-04-18T02:34:26Z","timestamp":1713407666000},"page":"103934","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["How to manage poor mobilisers"],"prefix":"10.1016","volume":"63","author":[{"given":"Nina","family":"Worel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.transci.2024.103934_bib1","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1038\/s41409-023-01943-3","article-title":"Hematopoietic cell transplantation and cellular therapies in Europe 2021. The second year of the SARS-CoV-2 pandemic. A Report from the EBMT Activity Survey","volume":"58","author":"Passweg","year":"2023","journal-title":"Bone Marrow Transpl [Internet]"},{"issue":"39","key":"10.1016\/j.transci.2024.103934_bib2","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1200\/EDBK_238693","article-title":"Chimeric antigen receptor T-cell therapies for aggressive B-cell lymphomas: current and future state of the art","author":"Abramson","year":"2019","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"16","key":"10.1016\/j.transci.2024.103934_bib3","doi-asserted-by":"crossref","first-page":"4816","DOI":"10.1182\/bloodadvances.2021006193","article-title":"Long-term safety for patients with tisagenlecleucel-treated relapsed\/refractory diffuse large B-cell lymphoma","volume":"6","author":"Jaeger","year":"2022","journal-title":"Blood Adv"},{"issue":"3","key":"10.1016\/j.transci.2024.103934_bib4","doi-asserted-by":"crossref","first-page":"277","DOI":"10.2217\/fon-2021-1090","article-title":"Idecabtagene vicleucel (ide-cel) CAR T-cell therapy for relapsed and refractory multiple myeloma","volume":"18","author":"Anderson Jr","year":"2022","journal-title":"Future Oncol"},{"issue":"3","key":"10.1016\/j.transci.2024.103934_bib5","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s40261-021-01012-x","article-title":"Comparative effectiveness research for CAR-T therapies in multiple myeloma: appropriate comparisons require careful considerations of data sources and patient populations","volume":"41","author":"Shah","year":"2021","journal-title":"Clin Drug Invest"},{"issue":"1","key":"10.1016\/j.transci.2024.103934_bib6","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/bjh.18176","volume":"198","author":"Achini\u2010Gutzwiller","year":"2022","journal-title":"Br J Haematol"},{"issue":"6","key":"10.1016\/j.transci.2024.103934_bib7","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1111\/j.1365-2141.2010.08313.x","article-title":"review: current status of stem cell mobilization","volume":"150","author":"Gertz","year":"2010","journal-title":"Br J Haematol"},{"issue":"7","key":"10.1016\/j.transci.2024.103934_bib8","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1038\/bmt.2014.39","article-title":"Autologous haematopoietic stem cell mobilisation in multiple myeloma and lymphoma patients: a position statement from the European Group for Blood and Marrow Transplantation","volume":"49","author":"Mohty","year":"2014","journal-title":"Bone Marrow Transpl"},{"issue":"8","key":"10.1016\/j.transci.2024.103934_bib9","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1016\/j.bbmt.2010.11.021","article-title":"Transplanted CD34+ cell dose is associated with long-term platelet count recovery following autologous peripheral blood stem cell transplant in patients with non-hodgkin lymphoma or multiple myeloma","volume":"17","author":"Stiff","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"10.1016\/j.transci.2024.103934_bib10","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.bbmt.2013.10.013","article-title":"Optimizing autologous stem cell mobilization strategies to improve patient outcomes: consensus guidelines and recommendations","volume":"20","author":"Giralt","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"issue":"10192","key":"10.1016\/j.transci.2024.103934_bib11","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(19)31240-1","article-title":"Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study","volume":"394","author":"Moreau","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.transci.2024.103934_bib12","first-page":"1","article-title":"Impact of daratumumab on stem cell mobilization and collection, engraftment and early post-transplant complications among multiple myeloma patients undergoing autologous stem cell transplantation","author":"Eleutherakis Papaiakovou","year":"2023","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"10.1016\/j.transci.2024.103934_bib13","doi-asserted-by":"crossref","first-page":"174.e1","DOI":"10.1016\/j.jtct.2022.11.029","article-title":"Stem cell mobilization yields with daratumumab- and lenalidomide-containing quadruplet induction therapy in newly diagnosed multiple myeloma: findings from the MASTER and GRIFFIN trials","volume":"29","author":"Chhabra","year":"2023","journal-title":"Transpl Cell Ther"},{"issue":"3","key":"10.1016\/j.transci.2024.103934_bib14","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/bmt.2011.82","article-title":"Proposed definition of \u2018poor mobilizer\u2019 in lymphoma and multiple myeloma: an analytic hierarchy process by ad hoc working group Gruppo ItalianoTrapianto di Midollo Osseo","volume":"47","author":"Olivieri","year":"2012","journal-title":"Bone Marrow Transpl"},{"issue":"2","key":"10.1016\/j.transci.2024.103934_bib15","doi-asserted-by":"crossref","first-page":"618","DOI":"10.3390\/jcm12020618","article-title":"Day -1 CD34+ cells and platelet count predict the number of apheresis in poor-mobilizer patients rescued by plerixafor","volume":"12","author":"Valentini","year":"2023","journal-title":"J Clin Med"},{"issue":"1","key":"10.1016\/j.transci.2024.103934_bib16","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.jcyt.2019.10.008","article-title":"Low baseline platelet count predicts poor response to plerixafor in patients with multiple myeloma undergoing autologous stem cell mobilization","volume":"22","author":"Bakeer","year":"2020","journal-title":"Cytotherapy"},{"issue":"12","key":"10.1016\/j.transci.2024.103934_bib17","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.2165\/11206040-000000000-00000","article-title":"Plerixafor","volume":"71","author":"Keating","year":"2011","journal-title":"Drugs"},{"issue":"11","key":"10.1016\/j.transci.2024.103934_bib18","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1517\/14712598.8.11.1797","article-title":"Plerixafor, a CXCR4 antagonist for the mobilization of hematopoietic stem cells","volume":"8","author":"Uy","year":"2008","journal-title":"Expert Opin Biol Ther"},{"issue":"28","key":"10.1016\/j.transci.2024.103934_bib19","doi-asserted-by":"crossref","first-page":"4767","DOI":"10.1200\/JCO.2008.20.7209","volume":"27","author":"DiPersio","year":"2009","journal-title":"J Clin Oncol"},{"issue":"23","key":"10.1016\/j.transci.2024.103934_bib20","doi-asserted-by":"crossref","first-page":"5720","DOI":"10.1182\/blood-2008-08-174946","article-title":"Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma","volume":"113","author":"DiPersio","year":"2009","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.transci.2024.103934_bib21","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1038\/sj.bmt.1705908","article-title":"AMD3100 plus G-CSF can successfully mobilize CD34+ cells from non-Hodgkin\u2019s lymphoma, Hodgkin\u2019s disease and multiple myeloma patients previously failing mobilization with chemotherapy and\/or cytokine treatment: compassionate use data.","volume":"41","author":"Calandra","year":"2008","journal-title":"Bone Marrow Transpl"},{"issue":"5","key":"10.1016\/j.transci.2024.103934_bib22","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1111\/j.1537-2995.2010.02896.x","volume":"51","author":"Worel","year":"2011","journal-title":"Transfus (Paris)"},{"issue":"8","key":"10.1016\/j.transci.2024.103934_bib23","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1038\/bmt.2010.249","article-title":"Plerixafor with and without chemotherapy in poor mobilizers: results from the German compassionate use program","volume":"46","author":"H\u00fcbel","year":"2011","journal-title":"Bone Marrow Transpl"},{"issue":"4","key":"10.1016\/j.transci.2024.103934_bib24","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1002\/jca.21496","article-title":"Plerixafor as preemptive strategy results in high success rates in autologous stem cell mobilization failure","volume":"32","author":"Worel","year":"2017","journal-title":"J Clin Apher"},{"issue":"11","key":"10.1016\/j.transci.2024.103934_bib25","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1038\/bmt.2012.60","article-title":"Growth factor plus preemptive (\u2018just-in-time\u2019) plerixafor successfully mobilizes hematopoietic stem cells in multiple myeloma patients despite prior lenalidomide exposure","volume":"47","author":"Costa","year":"2012","journal-title":"Bone Marrow Transpl"},{"issue":"11","key":"10.1016\/j.transci.2024.103934_bib26","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1016\/j.jcyt.2014.05.003","article-title":"Pharmacoeconomic impact of up-front use of plerixafor for autologous stem cell mobilization in patients with multiple myeloma","volume":"16","author":"Kim","year":"2014","journal-title":"Cytotherapy"},{"issue":"9","key":"10.1016\/j.transci.2024.103934_bib27","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.bbmt.2008.07.004","article-title":"Impact of mobilization and remobilization strategies on achieving sufficient stem cell yields for autologous transplantation","volume":"14","author":"Pusic","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"10.1016\/j.transci.2024.103934_bib28","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.bbmt.2009.11.012","article-title":"Poor mobilization of hematopoietic stem cells\u2014definitions, incidence, risk factors, and impact on outcome of autologous transplantation","volume":"16","author":"Wuchter","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"10.1016\/j.transci.2024.103934_bib29","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/bmt.2010.78","article-title":"Development and validation of a decision-making algorithm to guide the use of plerixafor for autologous hematopoietic stem cell mobilization","volume":"46","author":"Costa","year":"2011","journal-title":"Bone Marrow Transpl"},{"issue":"5","key":"10.1016\/j.transci.2024.103934_bib30","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.bbmt.2014.02.002","article-title":"Peripheral blood CD34+ percentage at hematological recovery after chemotherapy is a good early predictor of harvest: a single-center experience","volume":"20","author":"Sorasio","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"10.1016\/j.transci.2024.103934_bib31","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1038\/sj.leu.2405035","article-title":"Effect of lenalidomide therapy on mobilization of peripheral blood stem cells in previously untreated multiple myeloma patients","volume":"22","author":"Mazumder","year":"2008","journal-title":"Leukemia"},{"issue":"21","key":"10.1016\/j.transci.2024.103934_bib32","doi-asserted-by":"crossref","first-page":"4079","DOI":"10.1182\/blood.V116.21.4079.4079","article-title":"Lenalidomide upregulates CXCR4 on CD34+ hematopoietic cells resulting in increased binding to bone marrow niche and inhibiting mobilization into peripheral blood in multiple myeloma patients","volume":"116","author":"Li","year":"2010","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.transci.2024.103934_bib33","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/j.bbmt.2009.02.011","article-title":"Impairment of filgrastim-induced stem cell mobilization after prior lenalidomide in patients with multiple myeloma","volume":"15","author":"Popat","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.transci.2024.103934_bib34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/20406207231174304","article-title":"Innovations in hematopoietic stem-cell mobilization: a review of the novel CXCR4 inhibitor motixafortide","volume":"14","author":"Crees","year":"2023","journal-title":"Ther Adv Hematol"},{"issue":"4","key":"10.1016\/j.transci.2024.103934_bib35","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1038\/s41591-023-02273-z","article-title":"Motixafortide and G-CSF to mobilize hematopoietic stem cells for autologous transplantation in multiple myeloma: a randomized phase 3 trial","volume":"29","author":"Crees","year":"2023","journal-title":"Nat Med"},{"issue":"6","key":"10.1016\/j.transci.2024.103934_bib36","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1038\/s41591-020-0880-x","article-title":"BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial","volume":"26","author":"Bockorny","year":"2020","journal-title":"Nat Med"}],"container-title":["Transfusion and Apheresis Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1473050224001022?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1473050224001022?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,18]],"date-time":"2024-05-18T11:59:35Z","timestamp":1716033575000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1473050224001022"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":36,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["S1473050224001022"],"URL":"https:\/\/doi.org\/10.1016\/j.transci.2024.103934","relation":{},"ISSN":["1473-0502"],"issn-type":[{"value":"1473-0502","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"How to manage poor mobilisers","name":"articletitle","label":"Article Title"},{"value":"Transfusion and Apheresis Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.transci.2024.103934","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"103934"}}